Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

PURPOSE: Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emergi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Lin, Jessica J., Zhu, Viola W., Yoda, Satoshi, Yeap, Beow Y., Schrock, Alexa B., Dagogo-Jack, Ibiayi, Jessop, Nicholas A., Jiang, Ginger Y., Le, Long P., Gowen, Kyle, Stephens, Philip J., Ross, Jeffrey S., Ali, Siraj M., Miller, Vincent A., Johnson, Melissa L., Lovly, Christine M., Hata, Aaron N., Gainor, Justin F., Iafrate, Anthony J., Shaw, Alice T., Ou, Sai-Hong Ignatius
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5903999/
https://ncbi.nlm.nih.gov/pubmed/29373100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.2294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados